Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, Juan Carlos Hinojosa, Nicola Kerr, Maria Rosario, Stephen Toovey, Robert H. Arch, Margaret A. Phillips, Felix D. Rozenberg, Jade Bath, Caroline L. Ng, Annie N. Cowell, Elizabeth A. Winzeler, David A. Fidock, Mark Baker, Jörg J. Möhrle, Rob Hooft van Huijsduijnen, Nathalie Gobeau, Nada AraeipourNicole Andenmatten, Thomas Rückle, Stephan Duparc

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study'. Together they form a unique fingerprint.

Medicine & Life Sciences